此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

可解脱弹簧圈栓塞治疗慢性硬膜下血肿 (SEED)

2026年9月22日 更新者:Christopher P Kellner、Icahn School of Medicine at Mount Sinai

慢性硬膜下血肿可解脱弹簧圈栓塞治疗的安全性与有效性

This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).

研究概览

详细说明

The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.

研究类型

观察性的

注册 (估计的)

150

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Arizona
      • Tucson、Arizona、美国、85711
    • California
      • San Deigo、California、美国、92093
        • 尚未招聘
        • University of California - San Deigo
        • 接触:
        • 首席研究员:
          • David Santiago-Dieppa, MD
      • Walnut Creek、California、美国、94598
    • Kentucky
      • Louisville、Kentucky、美国、40292
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 尚未招聘
        • Oklahoma University Medical Center
        • 首席研究员:
          • Hakeem Shakir, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment

描述

Inclusion criteria:

  • Age ≥ 18
  • Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
  • A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
  • Signed informed consent obtained by patient or Legal Authorized Representative (LAR)

Exclusion criteria:

  • Primary acute SDH
  • Prior MMAE in target territory
  • Premorbid mRS > 3
  • Common carotid stenosis >70% or prior carotid stent placement
  • Significant medical contraindication to angiography (kidney failure/disease)
  • Anatomical variations that would make MMA embolization difficult or unsafe
  • Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
  • Pregnancy
  • Life expectancy ≤ 1 year

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Participants with cSDH

All participants enrolled will be treated with the Balt coils.

  1. MMA embolization: Utilize Balt Coils as stand-alone with or without other embolics treatment.

  2. MMA embolization: Utilize Balt Coils in combination with or without embolics in surgical or bedside evacuation, such as:

    1. MMA embolization in combination with Balt coils post-surgical debridement, or
    2. MMA embolization using Balt coils alone, pre- or post-surgical debridement.

MMA embolization utilizing Balt Coils

其他名称:
  • Optima
  • OptiMax
  • OptiBlock
  • Optima系列产品线扩展

surgical or bedside evacuation

pre or post-surgical debridement

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in hematoma volume
大体时间:180 days

Change in hematoma volume based on CT imaging

180 days
Change in maximal thickness
大体时间:180 days

Change in maximal thickness based on CT imaging

180 days
Change in midline shift
大体时间:180 days

Change in midline shift (mm) based on CT imaging

180 days
Number of periprocedural major disabling stroke or any death
大体时间:30 days

Number of periprocedural major disabling stroke or any death

30 days
Number of participants with symptomatic recurrence progression requiring retreatment
大体时间:180 days

Number of participants with symptomatic recurrence progression of the SDH requiring retreatment

180 days

次要结果测量

结果测量
措施说明
大体时间
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
大体时间:180 days

Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor

180 days
Number of Acute successful embolization of the target vessel
大体时间:Immediately post-procedure

Determination of successful embolization based on angiographic imaging

Immediately post-procedure
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
大体时间:180 days

The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL.

180 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Christopher Kellner、Icahn School of Medicine at Mount Sinai
  • 首席研究员:Benjamin Yim、John Muir Health
  • 首席研究员:Alexander Coon、Carondelet Neurological Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月2日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2028年9月1日

研究注册日期

首次提交

2025年12月5日

首先提交符合 QC 标准的

2025年12月5日

首次发布 (实际的)

2025年12月18日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅